| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 522 | PT 1 | 91.57 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 5 | PT 1 | 97.74 |
| Stress Responses and Cortisol | 2021-2025 | 29 | PT 1 | 98.43 |
| Tryptophan and brain disorders | 2021-2025 | 69 | PT 1 | 97.81 |
| Cancer therapeutics and mechanisms | 2021-2025 | 28 | PT 1 | 97.68 |
| Computational Drug Discovery Methods | 2021-2025 | 300 | PT 2 | 95.96 |
| Cancer Mechanisms and Therapy | 2021-2025 | 176 | PT 1 | 89.91 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 255 | PT 1 | 91.67 |
| Urinary Tract Infections Management | 2021-2025 | 267 | PT 7 | 89.45 |
| HIV/AIDS drug development and treatment | 2021-2025 | 370 | PT 1 | 90.42 |
| Cancer Cells and Metastasis | 2021-2025 | 673 | PT 10 | 86.78 |
| Treatment of Major Depression | 2021-2025 | 243 | PT 1 | 90.58 |
| Lung Cancer Research Studies | 2021-2025 | 908 | PT 1 | 90.12 |
| Receptor Mechanisms and Signaling | 2021-2025 | 418 | PT 1 | 87.60 |
| Protein Degradation and Inhibitors | 2021-2025 | 732 | PT 2 | 87.14 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 857 | PT 3 | 84.87 |
| Reproductive tract infections research | 2021-2025 | 336 | PT 7 | 87.06 |
| HIV Research and Treatment | 2021-2025 | 846 | PT 3 | 87.30 |
| Epilepsy research and treatment | 2021-2025 | 957 | PT 5 | 86.57 |
| Pharmacological Receptor Mechanisms and Effects | 2021-2025 | 119 | PT 1 | 81.49 |
| Advanced Breast Cancer Therapies | 2021-2025 | 939 | PT 5 | 83.79 |
| Pregnancy and Medication Impact | 2021-2025 | 533 | PT 2 | 80.85 |
| Estrogen and related hormone effects | 2021-2025 | 620 | PT 9 | 76.88 |
| Pharmacogenetics and Drug Metabolism | 2021-2025 | 723 | PT 2 | 72.46 |
| Pharmacological Effects and Assays | 2021-2025 | 200 | PT 3 | 71.43 |
| Enzyme function and inhibition | 2021-2025 | 218 | PT 1 | 73.19 |
| Veterinary Oncology Research | 2021-2025 | 689 | PT 26 | 69.74 |
| bioluminescence and chemiluminescence research | 2021-2025 | 683 | PT 10 | 46.29 |